Overview

Discovery Stage IND EXEMPT Clinical Study - Etoposide Plus Methotrexate and Single Nucleotide Polymorphisms

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

- Correlate Topoisomerase II Gene Single Nucleotide Polymorphisms (SNPs) to Using Etoposide Therapeutic Effects of Treating Small Cell Lung Cancer (SCLC) - Correlate CYP450 3A4 Gene Single Nucleotide Polymorphisms (SNPs) to Using Etoposide Side Effects of Treating Small Cell Lung Cancer (SCLC) - Correlate Dihydrofolic-Acid Reductase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Therapeutic Effects of Treating Small Cell Lung Cancer (SCLC) - Correlate Dihydrofolate Reductase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Side Effects of Treating Small Cell Lung Cancer (SCLC) - Correlate Thymidylate Synthetase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Side Effects of Treating Small Cell Lung Cancer (SCLC)

Phase:

Phase 3

Details

Lead Sponsor:

Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair

Treatments:

Etoposide
Etoposide phosphate
Methotrexate